Published: 1 June 2017
Author(s): Bernardine H. Stegeman, Hans L. Vos, Frans M. Helmerhorst, Frits R. Rosendaal, Pieter H. Reitsma, Astrid van Hylckama Vlieg
Issue: June 2017
Section: Original Article

Use of ethinylestradiol, one of the active ingredients in combined oral contraceptives, affects the incidence of venous thrombosis. To explain why some women develop thrombosis when using oral contraceptives and others do not, we hypothesized a role for the first-pass metabolism of ethinylestradiol in the liver. We set out to determine the association between genetic variation in the first-pass metabolism of ethinylestradiol, venous thrombosis risk and the effect on Sex-hormone-binding-globulin (SHBG) levels.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.